A Preliminary Pharmacokinetic Comparison of Δ-9 Tetrahydrocannabinol and Cannabidiol Extract Versus Oromucosal Spray in Healthy Men and Women
Clinicians should consider the route of administration when prescribing THC:CBD formulations, as bioavailability may vary significantly between methods.
A randomized, placebo-controlled, double-blind, pilot study of cannabis-related driving impairment assessed by driving simulator and self-report
Clinicians should be aware of the potential driving impairments associated with cannabis use and advise patients accordingly, especially in states where cannabis is legalized.
A within-subject, double-blind, placebo-controlled randomized evaluation of the combined effects of cannabidiol and hydromorphone in a human laboratory pain model
In this double-blind laboratory study, low-dose oral cannabidiol (50 mg) enhanced the acute analgesic properties of 4 mg hydromorphone without increasing negative subjective effects or adverse events, whereas higher CBD doses (200 mg) increased adverse effects. CBD also successfully mitigated the psychomotor impairment caused by the opioid alone. These findings suggest that lower-dose CBD may hold clinical potential as an opioid-sparing adjunct for acute pain management.
A randomized clinical trial of low-dose cannabis extract in Alzheimer’s disease
Consider low-dose THC-CBD extracts as a potential adjunctive treatment for patients with Alzheimer's disease-associated dementia, while monitoring for safety and efficacy.
A Randomized Controlled Trial of the Safety and Efficacy of Dronabinol for Agitation in Alzheimer’s Disease
Consider dronabinol as a potential treatment option for managing agitation in Alzheimer's disease, especially in patients who have not responded well to traditional therapies.
Acute pancreatitis as a rare adverse event among cannabis users: A systematic review
Cannabis-induced acute pancreatitis should be considered in young patients presenting with acute abdominal pain and elevated pancreatic enzymes in the absence of gallstones or heavy alcohol use. Cessation of cannabis along with conservative supportive care yields favorable recovery without mortality.
Cannabis dosing and administration for sleep: a systematic review
Integrative physicians should consider cannabis as a potential treatment for sleep disorders, while paying close attention to dosing to maximize benefits and minimize risks.
Acute Effects of Oral Cannabinoids on Sleep and High‐Density EEG in Insomnia: A Pilot Randomised Controlled Trial
Consider the use of oral cannabinoids as a potential treatment option for patients with insomnia, while monitoring for individual responses and side effects.
Acute metabolic effects of cannabinoid receptor modulators during sequential hyperglycemic, euglycemic-hyperinsulinemic clamps in healthy individuals
In healthy men, acute administration of the cannabinoid receptor agonist nabilone enhanced peripheral insulin sensitivity while reducing fasting endocannabinoid levels, whereas the CB1 receptor antagonist CP-945,598 diminished insulin sensitivity in a dose-dependent manner. Neither agent acutely altered glucose-stimulated insulin secretion during hyperglycemic clamps, suggesting that cannabinoid modulation primarily impacts peripheral insulin action rather than beta-cell insulin release in humans.
A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome
This pilot study indicates that medicinal cannabis may be a feasible treatment option for adolescents with Tourette Syndrome, warranting further investigation in a fully powered trial.
